SCHEMBL30206144

SCHEMBL30206144

COC(=O)c1nc(-c2cncc3c2ncn3C)c(C2COC2)nc1Nc1ccc(N2CCOCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 3/20 0.39
▸ CDK4 P11802 2/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ CCNB1 P14635 1/20 0.39
▸ CCND1 P24385 1/20 0.39
▸ CCNE1 P24864 1/20 0.39
▸ ALK Q9UM73 2/20 0.38
▸ INSR P06213 1/20 0.38
▸ PKMYT1 Q99640 2/20 0.37
▸ SYK P43405 1/20 0.37
▸ JAK3 P52333 3/20 0.37
▸ LCK P06239 1/20 0.37
▸ CSF1R P07333 1/20 0.36
▸ EML4 Q9HC35 1/20 0.36
▸ LRRK2 Q5S007 2/20 0.36
▸ PTK2 Q05397 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ NTRK1 P04629 2/20 0.36
▸ YES1 P07947 2/20 0.36
▸ KDR P35968 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173457 1.00 CDK2 (0.39) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173475 0.95 CDK2 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL30206250 0.95 CDK2 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL24944167 0.92 EML4 (0.45) CDK2CDK4ALKSYKJAK3
SCHEMBL30205559 0.92 EML4 (0.45) CDK2CDK4ALKSYKJAK3
SCHEMBL30206147 0.89 PKMYT1 (0.41) CDK2CDK4ALKINSRPKMYT1
SCHEMBL30206202 0.88 PKMYT1 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173512 0.88 PKMYT1 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173533 0.87 BTK (0.38) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173439 0.87 PKMYT1 (0.38) CDK2CDK4CDK1CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 CDK2 177/4885CDK4 277/4885CDK1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback